Efficacy and safety of pimobendan in canine heart failure caused by myxomatous mitral valve disease

Authors

  • P. J. Smith,

    1. Royal (Dick) School of Veterinary Studies Hospital for Small Animals, University of Edinburgh, Easter Bush Veterinary Centre, Roslin, Edinburgh EH25 9RG
    Search for more papers by this author
    • P. Smith's current address is Martin Referral Services, Thera House, 43 Waverley Road, Kenilworth, Warwickshire CV8 1JL

  • A. T. French,

    1. Royal (Dick) School of Veterinary Studies Hospital for Small Animals, University of Edinburgh, Easter Bush Veterinary Centre, Roslin, Edinburgh EH25 9RG
    Search for more papers by this author
  • N. Van Israr̈l,

    1. Royal (Dick) School of Veterinary Studies Hospital for Small Animals, University of Edinburgh, Easter Bush Veterinary Centre, Roslin, Edinburgh EH25 9RG
    Search for more papers by this author
    • N. Van Israël's current address is ACAPULCO, Animal Cardiopulmonary Consultancy, Rue Winampanche 752, 4910 Theux, Belgium

  • S. G. W. Smith,

    1. The Scarsdale Veterinary Hospital, 45-47 Kedleston Road, Derby DE22 1FN
    Search for more papers by this author
  • S. T. Swift,

    1. Cheadle Hulme Veterinary Hospital, 2-4 Queens Road, Cheadle Hulme, Cheshire SK8 5LU
    Search for more papers by this author
  • A. J. Lee,

    1. Medical Statistics Unit, Public Health Services, University of Edinburgh, Medical School, Teviot Place, Edinburgh EH8 9AG
    Search for more papers by this author
  • B. M. Corcoran,

    1. Royal (Dick) School of Veterinary Studies Hospital for Small Animals, University of Edinburgh, Easter Bush Veterinary Centre, Roslin, Edinburgh EH25 9RG
    Search for more papers by this author
  • J. Dukes-McEwan

    1. Royal (Dick) School of Veterinary Studies Hospital for Small Animals, University of Edinburgh, Easter Bush Veterinary Centre, Roslin, Edinburgh EH25 9RG
    Search for more papers by this author
    • J. Dukes-McEwan's current address is Small Animal Hospital, Department of Veterinary Clinical Science, University of Liverpool, Crown Street, Liverpool L69 7EX


Abstract

Objectives: To evaluate the clinical efficacy and safety of pimobendan by comparing it with ramipril over a six-month period in dogs with mild to moderate heart failure (HF) caused by myxomatous mitral valve disease (MMVD).

Methods: This was a prospective randomised, single-blind, parallel-group trial. Client-owned dogs (n=43) with mild to moderate HF caused by MMVD were randomly assigned to one of two groups, which received either pimobendan (P dogs) or ramipril (R dogs) for six months. The outcome measures studied were: adverse HF outcome, defined as failure to complete the trial as a direct consequence of HF; maximum furosemide dose (mg/kg/day) administered during the study period; and any requirement for additional visits to the clinic as a direct consequence of HF.

Results: Treatment with pimobendan was well tolerated compared with treatment with ramipril. P dogs were 25 per cent as likely as R dogs to have an adverse HF outcome (odds ratio 4.09, 95 per cent confidence interval 1.03 to 16.3, P=0.046).

Clinical Significance: R dogs had a higher overall score and thus may have had more advanced disease than P dogs at baseline (P=0.04). These results should be interpreted cautiously but such a high odds ratio warrants further investigation.

Ancillary